Phase II Trial of Healthy-donor Derived Full-spectrum Microbiome Therapeutic MTP-101-C in Steroid Relapse/refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC) (FMT-ELIMINATE)

Multiple retrospective studies suggest that the administration of corticosteroids to treat irAEs is safe, and does not compromise efficacy of ICI therapy in cancer patients. While
67% of patients respond to corticosteroids, 33% of patients require biologic therapy such as TNFα inhibitors (e.g. infliximab), integrin α4β7 inhibitors (e.g. vedolizumab), or JAK/STAT inhibitors (e.g. tofactinib). This study aims to determine that distinct pathobionts govern the development of irCAE and IMC; and that the administration of hdFMT may reverse steroid-refractory irCAEs or IMC. The use of hdFMT has been shown to be effective in steroid and biologic (TNFα and/or integrin α₄β₇ inhibitor) refractory colitis in PD-1 and/or CTLA-4 ICI treated cancer patients in single-institution case series.

开始日期2024-10-31

申办/合作机构

University of Pittsburgh

[+1]

100 项与 Healthy-donor Derived Full-spectrum Microbiome(University of Pittsburgh) 相关的临床结果

登录后查看更多信息

100 项与 Healthy-donor Derived Full-spectrum Microbiome(University of Pittsburgh) 相关的转化医学

登录后查看更多信息

100 项与 Healthy-donor Derived Full-spectrum Microbiome(University of Pittsburgh) 相关的专利（医药）

登录后查看更多信息

项与 Healthy-donor Derived Full-spectrum Microbiome(University of Pittsburgh) 相关的文献（医药）

Journal of Crohn's and Colitis

Novel Microbial Engraftment Trajectories following Microbiota Transplantation Therapy in Ulcerative Colitis

Article

作者: Khoruts, Alexander ; Syal, Aneesh ; Moutsoglou, Daphne ; Staley, Christopher ; Nelson, Elizabeth C ; Kabage, Amanda J ; Vaughn, Byron P ; Fischer, Monika ; Lopez, Sharon ; Chen, Lulu

AbstractBackground and AimsMicrobiota transplant therapy is an emerging treatment for ulcerative colitis. One proposed mechanism for the benefit of microbiota transplant therapy is through engraftment of donor microbiota. However, the kinetics of engraftment are unknown. We identified SourceTracker as an efficient method both to determine engraftment and for the kinetic study of engrafting donor taxa to aid in determining the mechanism of how this therapy may treat ulcerative colitis.MethodsUlcerative colitis patients were treated with either encapsulated (drug name MTP-101C) or placebo capsules daily for eight weeks followed by a four-week washout period. Amplicon sequence data from donors and patients were analyzed using the Bayesian algorithm SourceTracker.ResultsTwenty-seven patients were enrolled, 14 to the placebo group and 13 to the microbiota transplant therapy group. Baseline Shannon and Chao1 indices negatively correlated with week 12 donor engraftment for patients treated with active drug capsules but not for placebo patients. SourceTracker engraftment positively correlated with the week 12 distance from donors measured using the Bray-Curtis similarity metric in treated patients but not with placebo. We identified engrafting taxa from donors in our patients as well as quantified the proportion of donor similarity or engraftment during weeks one through eight (active treatment) and week 12, four weeks after the last dose.ConclusionSourceTracker can be used as a simple and reliable method to quantify donor microbial community engraftment and donor taxa contribution in patients with ulcerative colitis and other inflammatory conditions treated with microbiota transplant therapy.

100 项与 Healthy-donor Derived Full-spectrum Microbiome(University of Pittsburgh) 相关的药物交易

登录后查看更多信息